Milan, April 27 (beraking latest news Health) – American pharmaceutical group Bristol Myers Squibb (Bms) announces that the company has chosen Leiden, the Netherlands, to host the new cell therapy manufacturing site in Europe, “taking advantage of the ‘region of sciences’ opportunity. of life ‘, expanding near Amsterdam, and the convenience of access for the shipment of patient cells – reads a note – as part of its commitment to patients with aggressive hematological cancers and its growing franchise in therapies cell phones, BMS is dedicated to a new investment to enhance global production capacity and deliver treatments to patients more quickly, “the company underlines. “Leiden will be the company’s fifth state-of-the-art cell therapy manufacturing center and the first in Europe, adding to important manufacturing partnerships globally.”
“The key element of BMS commitment to cell therapies is the continued investment in advanced manufacturing capabilities, the expansion of our global network and the ability to treat patients, reducing delivery times and optimizing costs – says Ann Lee. , Senior Vice President, Cell Therapy Development & Operations, Bristol Myers Squibb – We continue to grow our presence in Europe and particularly the Netherlands, which offers an innovative hub for life sciences and global industrial talent. in the next few years hundreds of talented people who will be able to join our global team and participate in our journey in the field of cell therapies “.
The European headquarters – it is specified in the note – will be commercially focused on the production of multi-product cell therapies and on increasing production capacity. It will leverage innovative technologies, the latest manufacturing equipment and advanced digital systems to ensure patient access to cell therapies. The design and development of the site is underway and construction is expected to begin later this year.
COPYRIGHT today © breaking latest news